Press release no 5-2014
The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO of the company from January 12th, 2015.
Mr Gårdemyr has more than 30 years of international experience from the pharmaceutical and biotech industry. His experience includes management, business development, mergers & acquisitions, global marketing and commercial strategy. He holds the position as Corporate Advisor for Acino Pharma in Basel, Switzerland today. Prior to this position, he was Senior Vice President, Corporate Development/M&A, Global Business Development, Nycomed and Senior Vice President, Global Marketing, Takeda in Zurich, Switzerland, where he was in charge of the commercial assessment of external business development licensing opportunities.
Mr Gårdemyr started his career in Astra, followed by Ferring, Tigran Technologies and Retinalyze.
He has a Bachelor of Science in Business Administration and Economics from the University of Lund, Sweden.
Jónas Einarsson, Chairman of Targovax, says, “We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar’s track record and knowledge reflects Targovax` potential. His leadership will accelerate the company’s further development”.
“We are very grateful to Hanne Mette D. Kristensen for her contribution by leading Targovax from establishment to a phase II company”, says Jónas Einarsson.
Jonas Einarsson, Chairman of the Board, cell phone: +47 48 09 63 55
E-mail: firstname.lastname@example.org, (Press contact)
Targovax was established in October in 2010 to develop immunotherapy in the form of therapeutic cancer vaccines based on pioneering research at the Norwegian Radium Hospital and Norsk Hydro. Mutation of RAS is an early mutation in the transformation of a normal cell into a cancer cell. Lead candidate TG01 educates the body’s immune system to recognize and kill cancer cells with RAS mutations. TG01 has Orphan Drug status for pancreatic cancer in the EU and US and is currently in Phase II trials in operated pancreatic cancer, patients start treatment up to 12 weeks after surgery. The company is located in Lysaker, close to Oslo, Norway.
Immuno- oncology / Cancer vaccines
The Norwegian cancer research community has been in the forefront of understanding the mechanisms for immuno-oncology and cancer vaccines. A cancer vaccine educates the body’s immune system to recognize and kill the cancer cells. The TG01 vaccine is therapeutic and is given as treatment to patients after surgery of cancer patients, to prevent relapse.
Pancreas cancer and other RAS-mutated cancer forms
Pancreatic cancer is a disease affecting 116 000 patients each year in EU and USA, and approximately 690 persons each year in Norway. Approx 15-20% of these are discovered at an early stage and are operable. The mortality is high, and the prognosis for these patients has been more or less unchanged the last 30 years.
Approximately 80-90% of patients with pancreatic cancer have RAS mutations in the cancer cells.
RAS mutations occur in approx. 20% of all cancer cases, and are also frequent in colorectal cancer, non-small cell lung cancer and other cancers. Patients with RAS mutations within these indications have proved to be difficult to treat with current treatments, and there is a significant unmet medical need.